Robert R. Ruffolo - Sep 10, 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC (LBRX)

Role
Director
Signature
/s/ Marc Panoff, Attorney-in-Fact
Stock symbol
LBRX
Transactions as of
Sep 10, 2025
Transactions value $
$0
Form type
4
Date filed
9/12/2025, 06:25 PM
Previous filing
May 20, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RUFFOLO ROBERT R Director C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK /s/ Marc Panoff, Attorney-in-Fact 2025-09-12 0001187308

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LBRX Stock Option (Right to Buy) Disposed to Issuer -1.79K -100% 0 Sep 10, 2025 Common Stock 1.79K $69.72 Direct F1, F2
transaction LBRX Stock Option (Right to Buy) Award +1.79K 1.79K Sep 10, 2025 Common Stock 1.79K $15.00 Direct F1, F2
transaction LBRX Stock Option (Right to Buy) Disposed to Issuer -717 -100% 0 Sep 10, 2025 Common Stock 717 $69.72 Direct F1, F2
transaction LBRX Stock Option (Right to Buy) Award +717 717 Sep 10, 2025 Common Stock 717 $15.00 Direct F1, F2
transaction LBRX Stock Option (Right to Buy) Disposed to Issuer -10.8K -100% 0 Sep 10, 2025 Common Stock 10.8K $41.84 Direct F2, F3
transaction LBRX Stock Option (Right to Buy) Award +10.8K 10.8K Sep 10, 2025 Common Stock 10.8K $15.00 Direct F2, F3
transaction LBRX Stock Option (Right to Buy) Award $0 +22.4K $0.00 22.4K Sep 10, 2025 Common Stock 22.4K $15.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
F3 One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4 The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.